Guillou P J, Ramsden C W, Somers S S, Sedman P C
University Department of Surgery, St James's University Hospital, Leeds, UK.
Br J Cancer. 1989 Apr;59(4):515-21. doi: 10.1038/bjc.1989.106.
Serum-free supernatants from in vitro maintained gastrointestinal cancer and melanoma cell lines inhibit the generation of lymphokine (IL-2) activated killer (LAK) cells in a time and dose-related manner. Concentrations as low as 5% can inhibit the generation of LAK cytotoxicity but inhibition of proliferation is not observed until higher concentrations are included in the culture system. Inhibition is not observed with supernatants from a breast cancer cell line nor with supernatants from normal cells. There was complete concordance between the capacity of the tumour cells themselves to inhibit LAK generation and the presence of inhibitory activity in the corresponding supernatant. The inhibitory factor(s) is stable after heating to 44 and 56 degrees C. Production of the inhibitory factor(s) is sensitive to metabolic inhibitors and has a molecular weight greater than 25 kD. The inhibition of LAK cell stimulation by tumour cells may partially explain the failure of adoptively transferred LAK cells and IL-2 therapy to cause tumour regression in man.
体外培养的胃肠道癌细胞系和黑色素瘤细胞系的无血清上清液,能以时间和剂量相关的方式抑制淋巴因子(IL-2)激活的杀伤(LAK)细胞的生成。低至5%的浓度就能抑制LAK细胞毒性的产生,但直到培养体系中加入更高浓度时才观察到对增殖的抑制作用。乳腺癌细胞系的上清液以及正常细胞的上清液均未观察到抑制作用。肿瘤细胞自身抑制LAK细胞生成的能力与相应上清液中抑制活性的存在完全一致。抑制因子在加热至44和56摄氏度后仍稳定。抑制因子的产生对代谢抑制剂敏感,分子量大于25 kD。肿瘤细胞对LAK细胞刺激的抑制作用可能部分解释了过继转移的LAK细胞和IL-2疗法在人体中未能导致肿瘤消退的原因。